MAPS’ mission includes educating the public honestly about the risks and benefits of psychedelics and marijuana. Students for Sensible Drug Policy (SSDP) mobilizes and empowers young people to participate in the political process, pushing for sensible policies to achieve a safer and more just future, while fighting back against counterproductive Drug War policies.
MAPS and SSDP share a mutual interest in rational, scientifically based education with respect to marijuana, MDMA, LSD, Ibogaine, and other substances, and also in promoting alternative models of regulation for these substances. Brought together by these shared values, MAPS and SSDP will co-host this benefit event with addresses by Rick and SSDP Executive Director Aaron Houston and Associate Director Jon Perri.
Videos from both organizations will be aired throughout the evening, with music and dancing to follow late into the night. We recommend purchasing a ticket soon to guarantee your entrance to this extraordinary evening of policy, medicine, and entertainment.
This event will feature auctions of rare psychedelic memorabilia, including laboratory glassware from Sasha Shulgin’s lab (Alexander “Sasha” Shulgin and his partner Ann documented the creation and exploration of MDMA, 2C-B, and hundreds of other psychedelic compounds in their books PIHKAL and TIHKAL), original visionary and limited addition artworks, signed Albert Hofmann collector’s items (Albert Hofmann, Ph.D., is the late chemist who invented LSD in 1938), and one-of-a-kind jewelry and custom clothing.
1301 Spruce St.
Boulder, Co 80302
The principles and practices of psychedelic psychotherapy workshop will be led by Rick Doblin, Ph.D. and Marcela Ot’alora G.L.P.C., (a co-therapist from our former MDMA-assisted psychotherapy for PTSD clinical study in Spain). Topics will revolve around therapist techniques utilized during MDMA-assisted psychotherapy, and will explore issues discussed in MAPS’ MDMA/PTSD Treatment Manual, lessons learned from MAPS MDMA/PTSD pilot study, and theoretical applications of these techniques for use outside of MDMA-assisted psychotherapy. MAPS’ MDMA/PTSD drug development program will also be discussed.